Current approved therapeutic strategies for IPF and LC treatment

hucMSCs treatment prevents pulmonary fibrosis by reducing circANKRD42-YAP1-mediated mechanical stiffness

A review of current and novel therapies for idiopathic pulmonary fibrosis - Rafii - Journal of Thoracic Disease

PDF) Molecular Mechanisms and Cellular Contribution from Lung

Enrico CLINI, Professor in Respiratory Medicine

PDF) Inhibitor of PD-1/PD-L1: a new approach may be beneficial for the treatment of idiopathic pulmonary fibrosis

Therapy for Fibrotic Diseases: Nearing the Starting Line

Interstitial lung disease guideline

PDF) Molecular Mechanisms and Cellular Contribution from Lung

Flowchart of the trial selection process. RCT: randomized controlled

Transforming growth factor (TGF)-β1-induced miR-133a inhibits myofibroblast differentiation and pulmonary fibrosis

A Review of the Treatment and Management of Idiopathic Pulmonary Fibrosis

Therapeutic approaches targeting molecular signaling pathways common to diabetes, lung diseases and cancer - ScienceDirect

Inhibition of LPA-LPAR1 and VEGF-VEGFR2 signaling in IPF

PureTech Presents Data for LYT-100 (Deupirfenidone) Supporting Design of Dose-Ranging Trial in Idiopathic Pulmonary Fibrosis (IPF) at European Respiratory Society International Congress 2022 - The Globe and Mail

Demographic data of the two dead patients during our study